402 related articles for article (PubMed ID: 34884633)
21. Epiregulin promotes hair growth via EGFR-medicated epidermal and ErbB4-mediated dermal stimulation.
Choi N; Kim WS; Oh SH; Sung JH
Cell Prolif; 2020 Sep; 53(9):e12881. PubMed ID: 32700456
[TBL] [Abstract][Full Text] [Related]
22. High epiregulin expression in human U87 glioma cells relies on IRE1α and promotes autocrine growth through EGF receptor.
Auf G; Jabouille A; Delugin M; Guérit S; Pineau R; North S; Platonova N; Maitre M; Favereaux A; Vajkoczy P; Seno M; Bikfalvi A; Minchenko D; Minchenko O; Moenner M
BMC Cancer; 2013 Dec; 13():597. PubMed ID: 24330607
[TBL] [Abstract][Full Text] [Related]
23. PGE2/EP3/SRC signaling induces EGFR nuclear translocation and growth through EGFR ligands release in lung adenocarcinoma cells.
Bazzani L; Donnini S; Finetti F; Christofori G; Ziche M
Oncotarget; 2017 May; 8(19):31270-31287. PubMed ID: 28415726
[TBL] [Abstract][Full Text] [Related]
24. Intratumoral epiregulin is a marker of advanced disease in non-small cell lung cancer patients and confers invasive properties on EGFR-mutant cells.
Zhang J; Iwanaga K; Choi KC; Wislez M; Raso MG; Wei W; Wistuba II; Kurie JM
Cancer Prev Res (Phila); 2008 Aug; 1(3):201-7. PubMed ID: 19138957
[TBL] [Abstract][Full Text] [Related]
25. [Mechanism of cross talk between tissue factor/active coagulation factor VII and epidermal growth factor receptor signalings in colon cancer cells in culture].
Chen HK; Dai Y; Wu T; Wang X; Wan YL; Tang JQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Dec; 49(6):931-936. PubMed ID: 29263461
[TBL] [Abstract][Full Text] [Related]
26. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
Hsu PC; Jablons DM; Yang CT; You L
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
[TBL] [Abstract][Full Text] [Related]
27. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
28. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
[TBL] [Abstract][Full Text] [Related]
29. Epiregulin-blocking antibody inhibits epiregulin-dependent EGFR signaling.
Iijima M; Anai M; Kodama T; Shibasaki Y
Biochem Biophys Res Commun; 2017 Jul; 489(1):83-88. PubMed ID: 28274874
[TBL] [Abstract][Full Text] [Related]
30. Epiregulin reprograms cancer-associated fibroblasts and facilitates oral squamous cell carcinoma invasion via JAK2-STAT3 pathway.
Wang Y; Jing Y; Ding L; Zhang X; Song Y; Chen S; Zhao X; Huang X; Pu Y; Wang Z; Ni Y; Hu Q
J Exp Clin Cancer Res; 2019 Jun; 38(1):274. PubMed ID: 31234944
[TBL] [Abstract][Full Text] [Related]
31. Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance.
Siu MK; Abou-Kheir W; Yin JJ; Chang YS; Barrett B; Suau F; Casey O; Chen WY; Fang L; Hynes P; Hsieh YY; Liu YN; Huang J; Kelly K
Oncotarget; 2014 Jun; 5(11):3770-84. PubMed ID: 25004126
[TBL] [Abstract][Full Text] [Related]
32. High expression of NEK2 promotes lung cancer progression and drug resistance and is regulated by mutant EGFR.
Chen C; Peng S; Li P; Ma L; Gan X
Mol Cell Biochem; 2020 Dec; 475(1-2):15-25. PubMed ID: 32761510
[TBL] [Abstract][Full Text] [Related]
33. Epiregulin (EREG) is upregulated through an IL-1β autocrine loop in Caco-2 epithelial cells with reduced CFTR function.
Massip-Copiz M; Clauzure M; Valdivieso ÁG; Santa-Coloma TA
J Cell Biochem; 2018 Mar; 119(3):2911-2922. PubMed ID: 29091309
[TBL] [Abstract][Full Text] [Related]
34. Epiregulin is required for lung tumor promotion in a murine two-stage carcinogenesis model.
Bauer AK; Velmurugan K; Xiong KN; Alexander CM; Xiong J; Brooks R
Mol Carcinog; 2017 Jan; 56(1):94-105. PubMed ID: 26894620
[TBL] [Abstract][Full Text] [Related]
35. Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands.
Yano S; Takeuchi S; Nakagawa T; Yamada T
Cancer Sci; 2012 Jul; 103(7):1189-94. PubMed ID: 22435662
[TBL] [Abstract][Full Text] [Related]
36. Changes of tumor microenvironment in non-small cell lung cancer after TKI treatments.
Chen S; Tang J; Liu F; Li W; Yan T; Shangguan D; Yang N; Liao D
Front Immunol; 2023; 14():1094764. PubMed ID: 36949948
[TBL] [Abstract][Full Text] [Related]
37. Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion.
Whitsett TG; Cheng E; Inge L; Asrani K; Jameson NM; Hostetter G; Weiss GJ; Kingsley CB; Loftus JC; Bremner R; Tran NL; Winkles JA
Am J Pathol; 2012 Jul; 181(1):111-20. PubMed ID: 22634180
[TBL] [Abstract][Full Text] [Related]
38. Epigenetic regulation of Amphiregulin and Epiregulin in colorectal cancer.
Bormann F; Stinzing S; Tierling S; Morkel M; Markelova MR; Walter J; Weichert W; Roßner F; Kuhn N; Perner J; Dietz J; Ispasanie S; Dietel M; Schäfer R; Heinemann V; Sers C
Int J Cancer; 2019 Feb; 144(3):569-581. PubMed ID: 30252132
[TBL] [Abstract][Full Text] [Related]
39. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer.
Regales L; Gong Y; Shen R; de Stanchina E; Vivanco I; Goel A; Koutcher JA; Spassova M; Ouerfelli O; Mellinghoff IK; Zakowski MF; Politi KA; Pao W
J Clin Invest; 2009 Oct; 119(10):3000-10. PubMed ID: 19759520
[TBL] [Abstract][Full Text] [Related]
40. Targeting epiregulin in the treatment-damaged tumor microenvironment restrains therapeutic resistance.
Wang C; Long Q; Fu Q; Xu Q; Fu D; Li Y; Gao L; Guo J; Zhang X; Lam EW; Campisi J; Sun Y
Oncogene; 2022 Nov; 41(45):4941-4959. PubMed ID: 36202915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]